Clinical trials
Advanced Tumors clinical trials
Below are recruiting advanced tumors clinical trials, each written for real people, not researchers. We’re tracking 1,354 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07646626RecruitingPhase 2
New antibody drugs for advanced HER2-positive cancers
This trial tests two new antibody drugs (SSGJ-705 and SSGJ-612), alone or combined with chemotherapy, in patients with advanced cancers that have a protein called HER2. The study aims to see if this combination can shrink tumors and help patients live longer.
Hangzhou, ZhejiangAges 18–75 - NCT07372625RecruitingPhase 1
How rezatapopt affects common drugs in advanced solid tumors with TP53 Y220C mutation
This trial tests how rezatapopt changes the way your body processes four common medicines (metformin, rosuvastatin, repaglinide, and midazolam) in people with advanced solid tumors that have a specific TP53 Y220C gene change. It helps doctors understand the right dose for future patients.
Denver, ColoradoAges 18 years+ - NCT07177937RecruitingPhase 1
Study of DXC014 for advanced solid tumors
This trial tests DXC014, a new drug, in people with advanced solid tumors, including prostate cancer. It aims to see if the drug is safe and effective.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05877430RecruitingPhase 1/Phase 2
Testing an anti-cancer drug plus pembrolizumab for advanced cancers
This Phase 1/2 study tests the safety and early signs of benefit from CJRB-101 when combined with pembrolizumab (Keytruda) in people with advanced or metastatic lung, head and neck, or melanoma cancer. It may help some participants, but the main goal is to see how safe the combination is and whether it can control cancer.
Irvine, CaliforniaAges 18 years+ - NCT07027488RecruitingPhase 1
Testing AB821 for advanced solid tumors that resist immunotherapy
This trial tests a new study drug, AB821, for people with advanced solid tumors that have stopped responding to standard treatments, especially immunotherapy. The goal is to see if AB821 can shrink tumors or slow their growth.
New Haven, ConnecticutAges 18 years+ - NCT05620732Recruiting
CAR-T treatment for advanced stomach or pancreatic cancer
This trial tests a customized immune-cell treatment (CAR-T) for advanced stomach or pancreatic cancer that cannot be removed by surgery. It aims to use cells engineered to target a specific tumor marker to shrink cancer or slow its growth.
Shenzhen, GuangdongAges 18–75 - NCT07156253RecruitingPhase 1
Study of SYN818 with olaparib for advanced solid tumors
This trial is testing a new drug, SYN818, combined with olaparib for people with advanced solid tumors that have certain genetic changes (BRCA mutations or related DNA repair problems). It may be an option if you have ovarian or HER2-negative breast cancer and other treatments are no longer working.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06771219RecruitingPhase 1
Testing SLV-154 for advanced cancers
This trial tests a new drug called SLV-154 for people whose advanced cancer has not responded to standard treatments. The goal is to see if SLV-154 can shrink tumors or slow cancer growth.
Newport Beach, CaliforniaAges 12 years+ - NCT05320588RecruitingPhase 1/Phase 2
Early test of a cancer treatment for advanced solid tumors
This early-phase study tests a new treatment in people with advanced (locally advanced or metastatic) solid tumors that have worsened or cannot be treated with standard therapies. It may help shrink tumors or slow growth, and it also helps doctors learn the safest way to use the medicine.
Austin, TexasAges 18 years+ - NCT06778863RecruitingPhase 1
A study of CLSP-1025 for adults with certain solid tumors
This trial tests a new drug called CLSP-1025 for people with advanced solid tumors that have a specific change in the p53 gene (R175H). The drug targets this change to help fight the cancer.
Scottsdale, ArizonaAges 18 years+ - NCT07280832RecruitingPhase 1/Phase 2
JMT108 for advanced melanoma and urinary tract cancer
This study tests a new drug called JMT108 for advanced melanoma or urinary tract cancer. It may help your immune system attack the cancer, and the study is checking if it is safe and how well it works.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07192120RecruitingPhase 1/Phase 2
MHB048C for advanced solid tumors
This trial is testing a new medicine called MHB048C for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can help shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06484816RecruitingPhase 1
TGRX-1942 study for advanced solid tumor or blood cancer
This trial tests an experimental drug (TGRX-1942) for people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goal is to find a safe dose and see how well the drug works.
Hangzhou, ZhejiangAges 18 years+ - NCT07730190RecruitingPhase 1
Testing TQB6426 for advanced solid tumors
This trial tests a new drug called TQB6426 for people with advanced solid tumors that have not responded to other treatments. The drug targets a protein called GPC3 found on some tumors, aiming to deliver a powerful therapy directly to the cancer cells.
Hefei, AnhuiAges 18–75 - NCT05687136RecruitingPhase 1
Study two targeted drugs for solid tumors with DNA repair changes
This Phase 1 trial tests how safe and effective two anti-cancer drugs (peposertib and tuvusertib) are for advanced solid tumors. It focuses on cancers with specific DNA repair and cell-growth gene changes, aiming to shrink tumors and improve outcomes when standard treatments have stopped working.
Bethesda, MarylandAges 18 years+ - NCT07128303RecruitingPhase 1
Study of a new drug for advanced solid tumors with a specific genetic feature
This trial tests a new drug (GS-5319) for adults with advanced solid tumors that have a specific genetic feature called MTAP deficiency. The drug may be given alone or with another treatment, and the goal is to see if it can shrink tumors or slow their growth.
Boston, MassachusettsAges 18 years+ - NCT06880549RecruitingPhase 1
mRNA cancer vaccine study for advanced solid tumors
This study tests two new mRNA-based vaccines, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. It aims to see if the vaccines are safe and can help shrink or control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06736275RecruitingEarly Phase 1
Testing a new gene therapy for advanced solid tumors
This trial tests an experimental gene therapy called SXRN for people with advanced solid tumors that haven't responded to standard treatments. The study aims to see if it's safe and may help slow the disease.
BeijingAges 18–75 - NCT06782334RecruitingPhase 1/Phase 2
AMT-116 for advanced solid tumors
This trial tests a new drug called AMT-116 in people with advanced solid tumors that have not responded to prior treatment. The goal is to see if it is safe and effective.
Fuzhou, FujianAges 18 years+ - NCT04906434RecruitingPhase 1
Study of ABSK-011 for advanced solid tumors
This early-phase study tests how safe ABSK-011 is, what side effects it causes, and how the body processes the drug. It may help certain patients with advanced solid cancers (including some liver cancer cases) whose tumors have specific test results.
Phoenix, ArizonaAges 18–75 - NCT06413615RecruitingPhase 2
Study of a new targeted drug for advanced solid tumors with HER2
This study tests a new antibody-drug conjugate (FDA022-BB05) for people with advanced solid cancers—especially breast, endometrial, bladder, colorectal, or lung cancer—that have stopped responding to standard therapy. The drug targets HER2, a protein on some cancer cells, to try to shrink tumors or slow their growth.
ShanghaiAges 18–75 - NCT06710158RecruitingPhase 1
SC-102 for advanced solid tumors
This trial tests a new drug called SC-102 in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if SC-102 is safe and how well it works.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06770569RecruitingPhase 1
Study of HRS-3802 for advanced solid tumors
This trial tests an experimental drug called HRS-3802 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and how the body processes it.
Saint Leonards, New South WalesAges 18 years+ - NCT07639047RecruitingPhase 1
Testing AN8025 in Advanced Solid Cancers
This early-stage trial tests a new drug called AN8025 in people with advanced solid tumors (cancers that started in organs or tissues). The study aims to find the right dose and see if it helps patients whose cancers have grown despite other treatments.
Nedlands, Western AustraliaAges 18 years+
Hear when a new Advanced Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced tumors?
- Yes. Clin2 currently lists 1,354 recruiting advanced tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Advanced or Metastatic Solid Tumors
- Locally Advanced or Metastatic Solid Tumors
- Advanced Malignant Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Patients With Advanced Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.